Journal profile · Multiple
Rheumatology & Autoimmunity
ISSN 2767-1410 · eISSN 2767-1429 · John Wiley & Sons
Rheumatology & Autoimmunity: CAS Zone 4 · Medicine (2025 upgraded edition); impact factor 1.8 (journal website); fully open access; APC about USD 3,000; median 111 days to acceptance (69 articles, last 24 months); acceptance rate 15% (journal website); 57 articles in 2025; indexed in ESCI and Scopus.
Scope
Aims, scope and focus
Rheumatology & Autoimmunity is published by John Wiley & Sons and is in Zone 4 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Systemic Lupus Erythematosus Research, Rheumatoid Arthritis Research and Therapies and Diverse Scientific and Economic Studies, together about 26.4% of its articles. Its main subfields are Rheumatology. (generated from OpenAlex topic counts and CAS ranking data)
Rheumatology & Autoimmunity, hosted by Chinese Medical Association, is a peer-reviewed, open access journal focusing on cutting-edge research in rheumatology and autoimmune diseases. Rheumatology & Autoimmunity’s scope is broad, covering the basic, clinical, and translational medical advancements across the full spectrum of rheumatology and autoimmunity. This journal publishes a variety of article types including Original Article, Review, Editorial, Research Highlights, Consensus, Letter to the Editor, Commentary, Case Report, Meeting Report, Technical Note, Clinical Image, Brief Report, Study Protocols and Viewpoint. Readership: Academics, clinicians, researchers (students, post-doctoral researchers, and senior scientists) and other health-care professionals interested in rheumatology and autoimmunity research, as well as commercial and government organizations involved in drug development and clinical trials. Keywords: Internal Medicine, Immunology, Rheumatology, Pharmacology, Antibody, Laboratory Medicine, Arthritis, autoimmunity Indexing information Biological Abstracts (Clarivate Analytics) BIOSIS Previews (Clarivate Analytics) CAS: Chemical Abstracts Service (ACS) Directory of Open Access Journals (DOAJ) Emerging Sources Citation Index (Clarivate Analytics) SCOPUS (Elsevier) Web of Science (Clarivate Analytics)
From the journal's Aims & Scope
Research area (LetPub): Multiple
Main research topics OpenAlex counts of recent articles; shares are approximate
- Systemic Lupus Erythematosus ResearchMedicine13.4%
- Rheumatoid Arthritis Research and TherapiesMedicine7.9%
- Diverse Scientific and Economic StudiesEconomics, Econometrics and Finance5.2%
- Human auditory perception and evaluationEngineering5.2%
- Spondyloarthritis Studies and TreatmentsMedicine5%
- Autoimmune and Inflammatory Disorders ResearchMedicine5%
- Educational Robotics and EngineeringComputer Science4.5%
- Inflammasome and immune disordersBiochemistry, Genetics and Molecular Biology4.2%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Immunology | Zone 4 |
| Minor | Rheumatology | Zone 4 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Immunology | Zone 4 |
| Minor | Rheumatology | Zone 4 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Not covered
Not covered by this edition.
Database indexing
ESCIScopusDOAJLetPub
International journal early-warning lists: not listed in any editionLetPub
Indexing the journal's website claims
Web of ScienceCASPublisher website
As the journal's website lists them, not checked against each database; for Web of Science editions the records above apply.
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor (publisher) 2025
- 1.8Publisher website ·
- CiteScore 2026-06
- 2.3LetPub ·
- CiteScore (publisher) 2025
- 2.3Publisher website ·
- SJR 2026-06
- 0.5LetPub ·
- SNIP 2026-06
- 0.4LetPub ·
- h-index
- 12OpenAlex ·
- i10-index
- 15OpenAlex ·
- 2-year mean citedness
- 1.15OpenAlex ·
- Self-citation rate
- 16.7%LetPub ·
- Share of gold OA articles
- 100%LetPub ·
Volume
- Articles per year
- 31LetPub ·
- Articles per year (publisher) 2025
- 45Publisher website ·
- Downloads per year (publisher) 2025
- 79,227Publisher website ·
Articles by year OpenAlex count · 264 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 35 | 35 | 2 |
| 2025 | 57 | 57 | 62 |
| 2024 | 59 | 59 | 109 |
| 2023 | 45 | 45 | 78 |
| 2022 | 47 | 47 | 207 |
| 2021 | 21 | 21 | 57 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with Crossref · to
111 daysMedian, submission to acceptance · P25–P75 85 days – 152 days
- Acceptance to online
- median 56 days (71 articles)
- Submission to online
- median 178 days
- Sample
- 69 articles with submission and acceptance dates (97 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- about 11 weeksLetPub ·
- Acceptance rate (publisher) 2025
- 15%Publisher website ·
- Submission to first decision 2025
- 29 daysPublisher website ·
- Submission to acceptance 2025
- 127 daysPublisher website ·
- Acceptance to publication 2025
- 61 daysPublisher website ·
- Submission to publication (journal-reported)
- about 11 weeksDOAJ ·
- Peer review
- Single anonymous peer reviewDOAJ
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Fully open accessDOAJ
Every article is open access; authors usually pay an article processing charge (APC).
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| DOAJ | EUR 2,752 / GBP 2,310 / USD 3,000 | Yes | CC BY, CC BY-NC, CC BY-NC-ND | |
| OpenAlex | USD 3,000 / EUR 2,752 / GBP 2,310 | — | — | |
| LetPub | USD 3,000 / GBP 2,310 / EUR 2,752 | Yes | — |
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Profile
Publication details and official links
- Publisher
- John Wiley & Sons
- ISSN
- 2767-1410
- Electronic ISSN
- 2767-1429
- Society / sponsor
- Chinese Medical Association
- Official links
- Journal homepage ↗LetPub
- Author guidelines ↗LetPub
- Aims & Scope ↗LetPub
- Special issues ↗Publisher website
- APC information ↗DOAJ
- Fee waivers ↗DOAJ
- Open access statement ↗DOAJ
- License & copyright ↗DOAJ
- Peer review process ↗LetPub
- Editorial board ↗LetPub
- Plagiarism policy ↗DOAJ
FAQ
Frequently asked questions about Rheumatology & Autoimmunity
What CAS zone is Rheumatology & Autoimmunity in?
In the 2025 upgraded edition of the CAS Journal Ranking, Rheumatology & Autoimmunity is in Zone 4 of Medicine, and in Zone 4 of the minor category Immunology / Rheumatology. In the 2026 Xinrui edition it is in Zone 4 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Rheumatology & Autoimmunity?
The journal's website gives an impact factor of 1.8 (2025); this is the journal's own figure, as LetPub lists none for it; CiteScore 2.3, h-index 12.
How long does peer review take at Rheumatology & Autoimmunity?
Based on the dates recorded on 69 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 111 days (interquartile range 85–152 days); authors report an average review time of about 11 weeks; the journal's website gives an acceptance rate of 15% (2025). Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
Which databases index Rheumatology & Autoimmunity?
According to LetPub and DOAJ records, Rheumatology & Autoimmunity is indexed in ESCI, Scopus and DOAJ. The journal's website also lists Web of Science and CAS; that list has not been checked against each database.
Is Rheumatology & Autoimmunity open access, and what is the APC?
Rheumatology & Autoimmunity is a fully open-access journal. APC about USD 3,000.
Sources and updates
The facts on this page come from LetPub, Publisher website, OpenAlex, DOAJ; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-25). Last updated: .